Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation

作者：Xiaoyu Zhang, Yigeng Cao, Jialin Wei, Weihua Zhai, Qiaoling Ma, Chen Liang, Xin Chen, Wenbin Cao, Donglin Yang, Aiming Pang, Yi He, Sizhou Feng, Mingzhe Han, Rongli Zhang, Erlie Jiang · 发表于：American Journal of Hematology · 年份：2025 · DOI：10.1002/ajh.70026 · 被引用次数：6 · 研究领域：Acute Lymphoblastic Leukemia research、Chronic Myeloid Leukemia Treatments、CAR-T cell therapy research

Despite significant advancements in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), particularly the development of tyrosine kinase inhibitors (TKIs), the prognosis of refractory/relapsed (R/R) or persistent minimal residual disease (MRD)-positive Ph + ALL remains poor. For these patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the main approach for long-term disease-free survival [1]. However, post-transplantation relapses remain a major challenge. The remission depth is strongly associated with HSCT outcomes, highlighting the importance of achieving complete molecular remission (CMR) prior to transplantation [2]. The combination of TKIs and immune therapies has been the mainstay of therapy for Ph + ALL. The advent of targeted therapies such as the CD22 monoclonal antibody inotuzumab ozogamicin (INO) and the CD19 bispecific T-cell Engager (Blinatumomab, BiTE) has renewed interest in strategies to enhance disease remission while minimizing the cytotoxic effects of conventional chemotherapy [3, 4]. These advancements offer promising avenues for improving outcomes in high-risk patients. Olverembatinib, currently the only third-generation TKI available in mainland China, has demonstrated significant efficacy in treating chronic myeloid leukemia (CML) patients with the T315I mutation who are resistant to other TKIs [5]. However, its role in the treatment of R/R or MRD-positive Ph + ALL, particularly in hea...